ATTRACT 2025 Call results

ATTRACT – Accelerate Together Rare Cancer Treatment – is a pioneering charity partnership to stimulate clinical research on rare cancers. By mobilizing the best European scientists and enabling them to build the collaborations needed to address the challenges in this field, the ATTRACT consortium is for the second time making the best possible treatments accessible to rare cancer patients. Once again, ATTRACT has been able to rise to the challenge by providing significant resources to support 2 trials for a total funding of more than €11 million. 

International coordinator: Julien Edeline – Centre Eugène Marquis, Rennes FRANCE

Consortium: Julien Edeline (FR) / Angela Lamaca (ES) / Ivan Borbath (BE) / Marjolein Homs (NL) 

Biliary tract cancers (BTC) are rare cancers with a growing incidence and poor prognosis. They often harbour targetable molecular alterations. While precision medicine is already routinely used, in localized BTC, surgery is associated with a high risk of recurrence. This phase III trial aims to test a precision medicine approach in the adjuvant setting of localized BTC, after curative resection, to increase the relapse-free survival rate. 

International coordinator: Susana RIVES – Fundació Privada Per A La Recerca I La Docència Sant Joan De Déu (FSJD) / Hospital Sant Joan De Déu (HSJD), Esplugues de Llobregat SPAIN

Consortium: Susana Rives (ES) / Barbara De Moerloose (BE) / Friso Calkoen (NL) / André Baruchel (FR) / Franco Locatelli (IT)

ARI-0001 is the first fully academically developed CAR T-cell produced entirely in Europe for clinical application and approved by a regulatory agency. Currently, this cell product is approved in Spain under Hospital Exemption Clause for R/R ALL adult patients. The present study aims to extend the clinical evaluation of this therapy to paediatric patients, to fulfil EMA’s requirements for the Paediatric Investigational Plan. Of note, the confirmatory adult trial is supported by an ATTRACT 2023 grant.